CN100531712C - Dasatini sustained-release implants for treating entity tumor - Google Patents
Dasatini sustained-release implants for treating entity tumor Download PDFInfo
- Publication number
- CN100531712C CN100531712C CNB2007102027742A CN200710202774A CN100531712C CN 100531712 C CN100531712 C CN 100531712C CN B2007102027742 A CNB2007102027742 A CN B2007102027742A CN 200710202774 A CN200710202774 A CN 200710202774A CN 100531712 C CN100531712 C CN 100531712C
- Authority
- CN
- China
- Prior art keywords
- bms
- cancer
- tumor
- release
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 137
- 239000007943 implant Substances 0.000 title claims abstract description 123
- 238000013268 sustained release Methods 0.000 title claims description 71
- 239000012730 sustained-release form Substances 0.000 title claims description 71
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims abstract description 199
- 229960002448 dasatinib Drugs 0.000 claims abstract description 198
- 239000000463 material Substances 0.000 claims abstract description 37
- 230000001093 anti-cancer Effects 0.000 claims abstract description 27
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 8
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 7
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 7
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 7
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims description 57
- 239000007924 injection Substances 0.000 claims description 57
- 239000002253 acid Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 10
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 7
- 201000001514 prostate carcinoma Diseases 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000010174 renal carcinoma Diseases 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims description 5
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract description 94
- 239000003814 drug Substances 0.000 abstract description 40
- 229960004275 glycolic acid Drugs 0.000 abstract description 33
- 229920001577 copolymer Polymers 0.000 abstract description 31
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 abstract description 19
- 229950004403 polifeprosan Drugs 0.000 abstract description 19
- 239000002067 L01XE06 - Dasatinib Substances 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 201000007270 liver cancer Diseases 0.000 abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 2
- 201000004101 esophageal cancer Diseases 0.000 abstract description 2
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 40
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 31
- 229940079593 drug Drugs 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- 229930195725 Mannitol Natural products 0.000 description 30
- 239000000594 mannitol Substances 0.000 description 30
- 235000010355 mannitol Nutrition 0.000 description 30
- 230000002401 inhibitory effect Effects 0.000 description 29
- 239000004626 polylactic acid Substances 0.000 description 25
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 23
- 229920000747 poly(lactic acid) Polymers 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 description 8
- 229920000305 Nylon 6,10 Polymers 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 230000005760 tumorsuppression Effects 0.000 description 8
- 239000002131 composite material Substances 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- -1 chrondroitin Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940068117 sprycel Drugs 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A dasatinib slow release implant for treating solid tumor is characterized in that the slow release implant contains anti-cancer effective amount dasatinib, slow release supplementary materials and some slow release regulator. The solid tumors comprise lung cancer, esophagus cancer, stomach cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer and colorectal cancer. The slow release supplementary materials mainly are one or their combination of co-polymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate), and poly (L-lactide-co-propyl phosphate), during its degradation and absorption, slow releasing dasatinib to tumor local, so it greatly decreases its whole body toxicity reaction, at the same time it also maintains effective medicine concentration of tumor local. The tumor local is arranged with the slow release implant, which can not only decrease whole body toxicity reaction of dasatinib, but also selectively promote medicine concentration of the tumor local, reinforce therapeutic effect of non-operation therapy such as chemotherapeutic drugs, radiotherapy and etc.
Description
(1) technical field
The present invention relates to a kind of Dasatini sustained-release implants for the treatment of entity tumor, belong to technical field of pharmaceuticals.
(2) background technology
Though the research about cancer has obtained bigger progress, its mortality rate still occupies the prostatitis of the various common causes of the death.Up-to-date data show that China had 3,000,000 people to die from cancer in 2006.Cancer morbidity rises year by year and is rejuvenation trend, has data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, and mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Estimate that the year two thousand twenty China will have 4,000,000 people to die from cancer therefore every year, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.
BMS 354825 (Dasatinib, Dasatinib/Sprycel) belong to many tyrosine kinase inhibitors, be mainly used in and treat, comprise the adult patient of all stadium of chronic lymphocytic leukemia (chronic phase, accelerated period, lymphoid lineage cell acute transformation phase and myelocyte acute transformation phase) that imatinib mesylate (Imatinib mesylate/Gleevec) drug resistance maybe can not tolerate.Simultaneously, FDA also treats the male acute lymphoblastic leukemia adult patient of Philadelphia chromosome that maybe can not tolerate other therapy drug resistances through normal procedure approval Dasatinib.
BMS 354825 in clinical research the side reaction of normal report fluid retention, gastrointestinal symptom and bleeding episode etc. are arranged; The most serious side reaction of normal report is heating, pleural effusion, heat generation neutrophilic leukocyte minimizing, gastrointestinal hemorrhage, pneumonia, thrombocytopenia, dyspnea, anemia, diarrhoea and heart failure etc.
BMS 354825 it be unclear that the inhibitory action of other tumors, particularly other solid tumors.Though unite separately or with other anticarcinogen some tumor may be had certain effect by tool, limited its clinical practice by the caused whole body toxic and side effects of conventional route administration.
(3) summary of the invention
Based on above examination to prior art, the present invention compares other tumor, found that BMS 354825 has comparatively significantly action effect to entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer and rectal cancer.Discover that further the BMS 354825 local sustained release also has good therapeutical effect to the outer entity tumor of other craniums such as thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate.Yet conventional method is difficult to bring into play its anti-tumor effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of entity tumor, not only effect is obvious, and its general toxicity obviously alleviates.
The present invention treats the sustained-release implant of entity tumor, it is characterized in that this sustained-release implant contains the BMS 354825 of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:
(1) BMS 354825 0.1%-60%
(2) slow-release auxiliary material 40%-99%
(3) slow release regulator 0-15%
Decanedioic acid (SA) copolymer), a kind of or its combination among poly-(L-lactide-co-etherophosphoric acid) (p (LAEG-EOP)), poly-(L-lactide-co-phosphoric acid propyl ester) (p (DAPG-EOP)) slow-release auxiliary material of the present invention mainly is selected from the copolymer (PLGA), polifeprosan of polylactic acid (PLA), glycolic and hydroxyacetic acid (to carboxy phenyl propane (p-CPP):.
Wherein the molecular weight peak value of polylactic acid (PLA) is 5000-15000,10000-20000,20000-35000 or 30000-50000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.
The molecular weight peak value of the copolymer of glycolic and hydroxyacetic acid (PLGA) is 5000-15000,15000-35000,35000-45000 or 45000-80000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.The percentage by weight of glycolic and hydroxyacetic acid is 90:10,80:20,70:30,60:40,50:50 or 40:60; Wherein with 80:20,70:30,60:40,50:50 are preferred, with 60:40 and 50:50 for most preferably.
(to carboxy phenyl propane (p-CPP): the percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) decanedioic acid (SA) copolymer) is 10:90 to polifeprosan, 20:80,30:70,40:60,50:50 or 60:40; Wherein with 80:20,70:30,60:40,50:50 are preferred, with 60:40 and 50:50 for most preferably.
The molecular weight peak value of poly-(L-lactide-co-etherophosphoric acid) is 5000-15000,10000-20000,20000-35000 or 30000-50000, serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.
In " slow-release auxiliary material complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor), slow-release auxiliary material is had a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some slow-release auxiliary material.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above slow-release auxiliary material has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned slow-release auxiliary material, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.
For regulating other characteristic of drug releasing rate or change anti-cancer sustained-released implantation agent of the present invention, can change the monomer component of polymer or the composition and the proportioning of molecular weight, interpolation or adjusting slow-release auxiliary material, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar and salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt and sodium salt etc.
Characteristics of the present invention are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other slow-release auxiliary material.The slow-release auxiliary material of adding is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Slow-release auxiliary material also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned slow-release auxiliary material is applicable to the compositions that contains or do not contain additive.
The consumption of sustained-release implant depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 0.01-100 milligram/patient, is ideal with 1-50 milligram/patient, with 2-30 milligram/patient for the most desirable.
The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to, injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc., wherein implant is mainly sustained-release implant, controlled release implant or slowbreak implant; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and apperance; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferably for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant and sustained-release implant as selecting for use.
Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of compositions can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.
Each component and the weight percentage in compositions thereof are preferred one of following in the sustained-release implant:
(A) polylactic acid of the BMS 354825 of 1%-5% and 95%-99%;
(B) polylactic acid of the BMS 354825 of 5%-10% and 90%-95%;
(C) polylactic acid of the BMS 354825 of 10%-15% and 85%-90%;
(D) polylactic acid of the BMS 354825 of 15%-25% and 75%-85%;
(E) polylactic acid of the BMS 354825 of 25%-40% and 60%-75%;
(F) copolymer of the glycolic of the BMS 354825 of 1%-10% and 90%-99% and hydroxyacetic acid;
(G) copolymer of the glycolic of the BMS 354825 of 10%-20% and 80%-90% and hydroxyacetic acid;
(H) copolymer of the glycolic of the BMS 354825 of 20%-30% and 70%-80% and hydroxyacetic acid;
(I) copolymer of the glycolic of the BMS 354825 of 30%-40% and 60%-70% and hydroxyacetic acid;
(J) polifeprosan of the BMS 354825 of 5%-15% and 85%-95%;
(K) polifeprosan of the BMS 354825 of 15%-35% and 65%-85%;
(L) 5% BMS 354825 and 95% poly-(L-lactide-co-etherophosphoric acid);
(M) 10% BMS 354825 and 90% poly-(L-lactide-co-etherophosphoric acid);
(N) 20% BMS 354825 and 80% poly-(L-lactide-co-etherophosphoric acid);
(O) 30% BMS 354825 and 70% poly-(L-lactide-co-etherophosphoric acid);
(P) 5% BMS 354825 and 95% poly-(L-lactide-co-phosphoric acid propyl ester);
(Q) 10% BMS 354825 and 90% poly-(L-lactide-co-phosphoric acid propyl ester);
(R) 20% BMS 354825 and 80% poly-(L-lactide-co-phosphoric acid propyl ester);
(S) 30% BMS 354825 and 70% poly-(L-lactide-co-phosphoric acid propyl ester).
Each component and the weight percentage in compositions thereof are one of further preferred following in the sustained-release implant:
(A) mannitol of the polylactic acid of the BMS 354825 of 1%-5% and 85%-98% and 0.5%-15%;
(B) sorbitol of the polylactic acid of the BMS 354825 of 5%-10% and 90%-95% and 0.5%-10%;
(C) sodium chloride of the polylactic acid of the BMS 354825 of 10%-15% and 85%-90% and 0.5%-10%;
(D) mannitol of the polylactic acid of the BMS 354825 of 15%-25% and 75%-85% and 0.25%-5%;
(E) sorbitol of the polylactic acid 0.1%-8% of the BMS 354825 of 25%-40% and 60%-75%;
(F) mannitol of the copolymer of the glycolic of the BMS 354825 of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(G) sorbitol of the copolymer of the glycolic of the BMS 354825 of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(H) sodium chloride of the copolymer of the glycolic of the BMS 354825 of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(I) mannitol of the copolymer of the glycolic of the BMS 354825 of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
(J) mannitol of the polifeprosan of the BMS 354825 of 5%-15% and 85%-95% and 1%-5%;
(K) mannitol of the polifeprosan of the BMS 354825 of 15%-35% and 65%-85% and 0.25%-7.5%;
(L) 5% BMS 354825 and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(M) 10% BMS 354825 and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(N) 20% BMS 354825 and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(O) 30% BMS 354825 and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(P) 5% BMS 354825 and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(Q) 10% BMS 354825 and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(R) 20% BMS 354825 and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(S) 30% BMS 354825 and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.
Sustained-release implant is used for the treatment of entity tumor, comprise the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, tumor of head and neck and come from gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes, former or cancer, sarcoma or the carcinosarcoma of secondary.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.
Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Because anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
When used the part, said composition can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.
Anti-cancer composition of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.
Test one, BMS 354825 are to the inhibitory action of growth of tumour cell.
Be the inhibitory action of checking BMS 354825 to other growth of tumour cell, this test is added to BMS 354825 (15ug/ml) in 24 hours the various tumor cells of In vitro culture (table 1), continue to cultivate after 48 hours the counting cells sum and calculates its suppression ratio to growth of tumour cell (%).
The suppression ratio of growth of tumour cell (%)=((cellular control unit number-test group cell number)/cellular control unit number) * 100%
Table 1
| Tumor cell | Suppression ratio (%) |
| Hepatocarcinoma | 60 |
| Pulmonary carcinoma | 72 |
| The esophageal carcinoma | 68 |
| Gastric cancer | 70 |
| Breast carcinoma | 68 |
| Cancer of pancreas | 72 |
| Thyroid carcinoma | 68 |
| Nasopharyngeal carcinoma | 70 |
| Ovarian cancer | 76 |
| Carcinoma of endometrium | 80 |
| Cervical cancer | 70 |
| Renal carcinoma | 78 |
| Carcinoma of prostate | 74 |
| Bladder cancer | 72 |
| Colon cancer | 76 |
| Rectal cancer | 78 |
| Skin carcinoma | 58 |
| Carcinoma of testis | 58 |
The result of test one shows that compare with matched group, BMS 354825 all has obvious inhibitory action (P＜0.05) to the examination growth of tumor, and is wherein right.This is unexpected finds to constitute major technique feature of the present invention, for the treatment of entity tumor provides new selection.
The sustained-release implant that contains BMS 354825 can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing of implanting.
The preparation method of sustained-release implant of the present invention is as follows:
The slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.
Adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement.
Remove organic solvent.Vacuum drying or cold drying all can.
Dried solid composite is made different shape as required.
Ray sterilizing after the packing (roentgendosis is different because of volume) is standby.Also available other method sterilization.
(4) specific embodiment
Embodiment one,
The slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 10000-20000) of (90mg) of will weighing is put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 10 milligrams of BMS 354825, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% BMS 354825.The drug release time of this sustained-release implant in external normal saline is 12-16 days, is 14-18 days at the subcutaneous drug release time of mice.
Embodiment two
Make sustained-release implant by embodiment one described method, but contained anticancer effective component is one of following:
(A) 1% BMS 354825 and and 99% polylactic acid;
(B) 5% BMS 354825 and and 95% polylactic acid;
(C) 10% BMS 354825 and 90% polylactic acid;
(D) 15% BMS 354825 and 85% polylactic acid;
(E) 20% BMS 354825 and 80% polylactic acid.
Embodiment three
(molecular weight is the PLGA of 15000-25000 to the slow-release auxiliary material of (85mg) of will weighing, 50: 50) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add the 15mg BMS 354825, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 15% BMS 354825.The drug release time of this sustained-release implant in external normal saline is 14-24 days, is 16-26 days at the subcutaneous drug release time of mice.
Embodiment four
Make sustained-release implant by embodiment three described methods, contained anticancer effective component that different is is one of following:
(1) copolymer of the glycolic of the BMS 354825 of 1%-10% and 90%-99% and hydroxyacetic acid;
(2) copolymer of the glycolic of the BMS 354825 of 10%-20% and 80%-90% and hydroxyacetic acid;
(3) copolymer of the glycolic of the BMS 354825 of 20%-30% and 70%-80% and hydroxyacetic acid;
(4) copolymer of the glycolic of the BMS 354825 of 30%-40% and 60%-70% and hydroxyacetic acid;
The copolymer of (5) 5% BMS 354825 and 95% glycolic and hydroxyacetic acid;
The copolymer of (6) 10% BMS 354825 and 90% glycolic and hydroxyacetic acid;
The copolymer of (7) 20% BMS 354825 and 80% glycolic and hydroxyacetic acid;
The copolymer of (8) 30% BMS 354825 and 70% glycolic and hydroxyacetic acid.
Embodiment five
(molecular weight is the PLGA of 25000-30000 to the slow-release auxiliary material of (85mg) of will weighing, 75:25) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add 10mg BMS 354825 and 5mg mannitol, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% BMS 354825.The drug release time of this sustained-release implant in external normal saline is 20-24 days, is 20-28 days at the subcutaneous drug release time of mice.
Embodiment six
Make sustained-release implant by embodiment five described methods, contained anticancer effective component that different is is one of following:
(1) mannitol of the copolymer of the glycolic of the BMS 354825 of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(2) sorbitol of the copolymer of the glycolic of the BMS 354825 of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(3) sodium chloride of the copolymer of the glycolic of the BMS 354825 of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(4) mannitol of the copolymer of the glycolic of the BMS 354825 of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
The copolymer of (5) 5% BMS 354825 and 92% glycolic and hydroxyacetic acid and 2% sodium chloride;
The copolymer of (6) 10% BMS 354825 and 85% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (7) 20% BMS 354825 and 75% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (8) 30% BMS 354825 and 75% glycolic and hydroxyacetic acid and 5% mannitol.
Embodiment seven
85mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 50:50) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 15mg BMS 354825, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 15% Dasatini sustained-release implants.The drug release time of this sustained-release implant in external normal saline is 19-26 days, is 18-28 days at the subcutaneous drug release time of mice.
Embodiment eight
Make sustained-release implant by embodiment seven described methods, that contained anticancer effective component is is one of following but different is:
(1) polifeprosan of the BMS 354825 of 1%-15% and 85%-95%;
(2) polifeprosan of the BMS 354825 of 15%-35% and 65%-85%;
(3) 5% BMS 354825 and 95% polifeprosan;
(4) 10% BMS 354825 and 90% polifeprosan;
(5) 15% BMS 354825 and the polifeprosan of 85%-95%;
(6) 20% BMS 354825 and 80% polifeprosan.
Embodiment nine
80mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 30:70) and 5mg sodium chloride are put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 15mg BMS 354825, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 15% Dasatini sustained-release implants.The drug release time of this sustained-release implant in external normal saline is 18-26 days, is 19-24 days at the subcutaneous drug release time of mice.
Embodiment ten
Make sustained-release implant by embodiment ten described methods, that contained anticancer effective component is is one of following but different is:
(1) mannitol of the polifeprosan of the BMS 354825 of 5%-15% and 85%-95% and 1%-5%; Or
(2) mannitol of the polifeprosan of the BMS 354825 of 15%-35% and 65%-85% and 0.25%-7.5%.
Embodiment 11
85mg slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) and 10mg mannitol are put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 5 milligrams of BMS 354825, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 5% BMS 354825.The drug release time of this sustained-release implant in external normal saline is 16-24 days, is 20-26 days at the subcutaneous drug release time of mice.
Embodiment 12
Make sustained-release implant by embodiment 11 described methods, used slow-release auxiliary material is selected from one of following or its combination:
(A) 1% BMS 354825 and and 95% polylactic acid and 4% mannitol;
(B) 5% BMS 354825 and and 93% polylactic acid and 2% mannitol;
(C) 10% BMS 354825 and 85% polylactic acid and 5% mannitol;
(D) 15% BMS 354825 and 82% polylactic acid and 3% sodium chloride;
(E) 20% BMS 354825 and 78% polylactic acid and 2% sodium chloride.
Embodiment 13
Make sustained-release implant by embodiment 1 to 11 described method, used slow-release auxiliary material is selected from one of following or its combination:
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,15000-35000,35000-45000 or 45000-80000 and the copolymer of hydroxyacetic acid (PLGA);
C) polifeprosan is (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) copolymer), be 10:90,20:80,30:70,40:60,50:50 or 60:40 to the percentage by weight of carboxy phenyl propane (p-CPP) and decanedioic acid (SA).
On the basis of above-mentioned slow release, the present invention finds that further body is implanted into BMS 354825 other entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer, rectal cancer, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate are also had good therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.Following in vivo test is used for explanation but not limitation of the present invention.
Embodiment 14
With 70,80,90 and 95mg molecular weight peak value be that the p (LAEG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg BMS 354825 respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% BMS 354825 again.The drug release time of this slow releasing agent in external normal saline is 22-26 days, is about 25-30 days at the subcutaneous drug release time of mice.
Embodiment 15
The method step that is processed into sustained-release implant is identical with embodiment 14, but the molecular weight peak value of different is p (LAEG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) 1%-5% BMS 354825;
(2) 5%-10% BMS 354825;
(3) 10%-20% BMS 354825;
(4) 20%-40% BMS 354825;
The sodium chloride of (5) 5% BMS 354825 and 92% p (LAEG-EOP) and 2%;
The mannitol of (6) 10% BMS 354825 and 85% p (LAEG-EOP) and 5%;
The mannitol of (7) 20% BMS 354825 and 75% p (LAEG-EOP) and 5%;
The mannitol of (8) 30% BMS 354825 and 75% p (LAEG-EOP) and 5%.
Embodiment 16
With 70,80,90 and 95mg molecular weight peak value be that the p (DAPG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg BMS 354825 respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% BMS 354825 again.The drug release time of this slow releasing agent in external normal saline is 16-22 days, is about 22-28 days at the subcutaneous drug release time of mice.
Embodiment 17
The method step that is processed into sustained-release implant is identical with embodiment 16, but the molecular weight peak value of different is p (DAPG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) 1%-5% BMS 354825;
(2) 5%-10% BMS 354825;
(3) 10%-20% BMS 354825;
(4) 20%-40% BMS 354825;
The sodium chloride of (5) 5% BMS 354825 and 92% p (DAPG-EOP) and 2%;
The mannitol of (6) 10% BMS 354825 and 85% p (DAPG-EOP) and 5%;
The mannitol of (7) 20% BMS 354825 and 75% p (DAPG-EOP) and 5%;
The mannitol of (8) 30% BMS 354825 and 75% p (DAPG-EOP) and 5%.
Embodiment 18, tumor are implanted into the inhibitory action of BMS 354825 to entity tumor
Method and step: tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, and (inoculation back the 8th day) is divided into 7 groups at random with animal, 10 every group when diameter of tumor grows to the 0.8cm left and right sides.Be normal saline group, BMS 354825 lumbar injection group (hereinafter to be referred as BMS 354825 abdominal cavity group), BMS 354825 local injection group (being called for short the BMS 354825 partial groups), high molecular polymer group (being called for short high poly-group), Dasatini sustained-release implants group with (5% group, 10% group of the made sustained-release implant of embodiment four, with 20% group, be called for short implant 5%, implant 10%, implant 20%).With 70% alcohol disinfecting tumor surface skin, selection is apart from tumor lower edge 1cm place, cut off the long otch of 1mm, with puncture needle with in the BMS 354825 implant implantation tumour tissue, not pastille high molecular polymer, BMS 354825 implant 5%, BMS 354825 implant 10%, BMS 354825 implant 20%.Sew up the incision and prevent that implant from spilling.Put to death animal in 15 days with vernier caliper measurement tumor size after the implant embedding in per 3 days, the back of weighing is complete peels off tumor and claims tumor heavy.Calculate tumor control rate %, DAS.ver1.0 pharmacology software is done statistical procedures.
Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%
Embodiment 19, tumor are implanted into the tumor-inhibiting action of BMS 354825 spit of fland sustained-release implant to Mice Bearing Lewis Lung Cancer
Check the tumor-inhibiting action of Dasatini sustained-release implants according to embodiment 18 described methods and step to Mice Bearing Lewis Lung Cancer.Used implant adjuvant is PLGA (molecular weight is 15000-30000, and the blending ratio of glycolic and hydroxyacetic acid is 50:50), is derived from embodiment four.The BMS 354825 implant of this experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 50%, 68%, 80%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments: tumor control rate is respectively 50%, 64%, 78%, compares with the local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and BMS 354825 local injection group and normal saline group comparison of tumor suppression ratio are 14% and 12%, and repeated experiments: tumor control rate is 18% and 13%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses BMS 354825 lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 20 tumors are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to mouse breast cancer
Check the tumor-inhibiting action of Dasatini sustained-release implants to mouse breast cancer according to embodiment 18 described methods and step, used implant is from embodiment one.Experimental result shows that the tumor control rate of 1%, 10% and 25% BMS 354825 implant is respectively 46%, 52%, 76%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 48%, 60%, 76%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 12% and 14%, and repeated experiments: tumor control rate is 13% and 12%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses BMS 354825 lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 21, tumor are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to rat liver cancer
Check the tumor-inhibiting action of Dasatini sustained-release implants according to embodiment 18 described methods and step to rat liver cancer, used implant is 5%, 10% and 20% polifeprosan (percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) is 50:50), from embodiment eight.The BMS 354825 implant of experimental result proof various dose is implanted in rat liver cancer (H22) entity tumor and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 44%, 58%, 76%, compares with BMS 354825 local injection group, and low dose group P value equals 0.001, and middle and high dosage group P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 46%, 56%, 76%, compares with BMS 354825 local injection group, and low dose group P value is less than 0.05, and middle and high dosage group P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and BMS 354825 local injection group and normal saline group comparison of tumor suppression ratio are 18% and 22%, and repeated experiments: tumor control rate is 25% and 16%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses BMS 354825 lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 22 tumors are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to the mice esophageal carcinoma
Check the tumor-inhibiting action of Dasatini sustained-release implants to the mice esophageal carcinoma according to embodiment 18 described methods and step, used implant is selected from embodiment six.The BMS 354825 implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 48%, 56%, 78%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments finds that tumor control rate is respectively 50%, 72%, 480%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 10% and 8%, and repeated experiments shows that tumor control rate is 12% and 10%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 23, tumor are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to mouse pancreas cancer
Check the tumor-inhibiting action of Dasatini sustained-release implants to mouse pancreas cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50:50).The content of BMS 354825 in sustained-release implant be 2.5%, 7.5% and the BMS 354825 implant of 12.5%. experimental result proof various dose implant in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 38%, 52%, 68%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 38%, 54%, 78%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 14%.Repeated experiments finds that tumor control rate is 10% and 14%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 24, tumor are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to the mice rectal cancer
Check the tumor-inhibiting action of Dasatini sustained-release implants to the mice rectal cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50:50).The content of BMS 354825 in sustained-release implant is the BMS 354825 implant of 7.5%, 15% and 25%. experimental results proof various dose, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 40%, 72%, 82%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 50%, 60%, 78%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 18%.Repeated experiments finds that tumor control rate is 12% and 15%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 25, tumor are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to the mice carcinoma of prostate
Check the tumor-inhibiting action of Dasatini sustained-release implants to the mice carcinoma of prostate according to embodiment 18 described methods and step, used implant adjuvant is p (LAEG-EOP) (molecular weight is 10000-25000).The content of BMS 354825 in sustained-release implant is 5%, 10% and 20% (from embodiment 14).The BMS 354825 implant of experimental result proof various dose is implanted in the nude mice model human prostata cancer entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 38%, 52%, 74%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 40%, 68%, 78%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 14%.Repeated experiments finds that tumor control rate is 12% and 14%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 26, tumor are implanted into the tumor-inhibiting action of Dasatini sustained-release implants to the mouse ovarian cancer
Check the tumor-inhibiting action of Dasatini sustained-release implants to the mouse ovarian cancer according to embodiment 18 described methods and step, used implant adjuvant is p (DAPG-EOP) (molecular weight is 10000-25000).The content of BMS 354825 in sustained-release implant is 5%, 10% and 20% (from embodiment 16).The content of BMS 354825 in sustained-release implant is 7.5%, 15% and 25%.The BMS 354825 implant of experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.BMS 354825 implant tumor control rate is respectively 34%, 50%, 62%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 32%, 48%, 66%, compares with BMS 354825 local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.BMS 354825 lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 16% and 8%.Repeated experiments finds that tumor control rate is 8% and 12%.The tumour inhibiting rate of BMS 354825 implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
In addition, tumor is implanted into Dasatini sustained-release implants other entity tumors such as gastric cancer, bladder cancer, carcinoma of testis, colon cancer, carcinoma of endometrium, lymphoma, the cerebral tumor, cervical cancer, renal carcinoma is also had good therapeutical effect, and its effect obviously surpasses BMS 354825 lumbar injection group and local injection group.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.
Claims (3)
- [claim 1] a kind of Dasatini sustained-release implants for the treatment of entity tumor is characterized in that this sustained-release implant contains the BMS 354825 and the slow-release auxiliary material of effective anticancer, and wherein the weight ratio of each constituent is:(1) anticancer effective component is 30% BMS 354825, and slow-release auxiliary material is that 70% molecular weight peak value is poly-(the L-lactide-co-etherophosphoric acid) of 10000-25000;(2) anticancer effective component is 20% BMS 354825, and slow-release auxiliary material is that 80% molecular weight peak value is poly-(the L-lactide-co-etherophosphoric acid) of 10000-25000;(3) anticancer effective component is 10% BMS 354825, and slow-release auxiliary material is that 90% molecular weight peak value is poly-(the L-lactide-co-etherophosphoric acid) of 10000-25000;(4) anticancer effective component is 5% BMS 354825, and slow-release auxiliary material is that 95% molecular weight peak value is poly-(the L-lactide-co-etherophosphoric acid) of 10000-25000;(5) anticancer effective component is 30% BMS 354825, and slow-release auxiliary material is that 70% molecular weight peak value is poly-(the L-lactide-co-phosphoric acid propyl ester) of 10000-25000;(6) anticancer effective component is 20% BMS 354825, and slow-release auxiliary material is that 80% molecular weight peak value is poly-(the L-lactide-co-phosphoric acid propyl ester) of 10000-25000;(7) anticancer effective component is 10% BMS 354825, and slow-release auxiliary material is that 90% molecular weight peak value is poly-(the L-lactide-co-phosphoric acid propyl ester) of 10000-25000; Or(8) anticancer effective component is 5% BMS 354825, and slow-release auxiliary material is that 95% molecular weight peak value is poly-(the L-lactide-co-phosphoric acid propyl ester) of 10000-25000.
- The sustained-release implant that [claim 2] claim 1 is described is characterized in that this sustained-release implant is in the tumor or the slow releasing injection and the solid sustained-release implant of all injections of tumor or placement.
- The sustained-release implant that [claim 3] is according to claim 1 is characterized in that described sustained-release implant is used for the preparation treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, tumor of head and neck and originate from gallbladder, the oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, former or the cancer of secondary of eyes, the pharmaceutical preparation of sarcoma or carcinosarcoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007102027742A CN100531712C (en) | 2007-11-29 | 2007-11-29 | Dasatini sustained-release implants for treating entity tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007102027742A CN100531712C (en) | 2007-11-29 | 2007-11-29 | Dasatini sustained-release implants for treating entity tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101161235A CN101161235A (en) | 2008-04-16 |
| CN100531712C true CN100531712C (en) | 2009-08-26 |
Family
ID=39296266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007102027742A Expired - Fee Related CN100531712C (en) | 2007-11-29 | 2007-11-29 | Dasatini sustained-release implants for treating entity tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100531712C (en) |
-
2007
- 2007-11-29 CN CNB2007102027742A patent/CN100531712C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101161235A (en) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101185633A (en) | Neratinib sustained-release implant for treating solid tumor | |
| CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
| CN101185627B (en) | Nilotinib sustained-release implant for treating solid tumor | |
| CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
| CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
| CN100563645C (en) | A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
| CN100531712C (en) | Dasatini sustained-release implants for treating entity tumor | |
| CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
| CN100531711C (en) | Erlotinib sustained-release implants for treating entity tumor | |
| CN101204368A (en) | Pirarubicin sustained-release implant treating for solid tumor | |
| CN101185632A (en) | Lonafarnib sustained-release implant for treating solid tumor | |
| CN101176710A (en) | Mitoxantrone sustained-release implantation agent for curing entity tumour | |
| CN101229120A (en) | Sustained release implant for treating solid tumors | |
| CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
| CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour | |
| CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors | |
| CN101219104A (en) | Cladribine sustained-release implantation agent for treating solid tumors | |
| CN101176716A (en) | Sunitinib sustained-release implantation agent for curing entity tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG ENDUO BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD. Effective date: 20110525 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE TO: 250101 201, NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110525 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201 Patentee after: Shandong many biological pharmaceutical Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: DASEN BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANDONG ENDUO BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201 Patentee after: DASEN BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201 Patentee before: Shandong many biological pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090826 Termination date: 20161129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |